XOMA Royalty Reports Strong FY25 Profit Turnaround, 83% Revenue Growth, and Significant Business Expansion
Summary
XOMA Royalty reported a major financial turnaround in FY25 with an 83% revenue increase, a shift from net loss to $31.7M net income, and significant business development including a $16M share buyback.
Key Events
-
Major Financial Turnaround
The company shifted from a $13.8 million net loss in fiscal year 2024 to a $31.7 million net income in fiscal year 2025.
-
Strong Revenue Growth
Total income and revenues increased by 83% to $52.1 million in fiscal year 2025, with royalties growing 68% compared to the prior year.
-
Significant Share Buyback
XOMA Royalty repurchased and retired 648,048 shares for an aggregate of $16.0 million in 2025, demonstrating a substantial return of capital.
-
Active Business Development
The company added 22 new assets and completed seven acquisitions, including a strategic Takeda royalty sharing agreement with up to $852.6 million in potential milestones.
Analysis
XOMA Royalty Corporation has reported a highly positive financial performance for fiscal year 2025, marking a significant turnaround from a net loss to substantial profitability. The company achieved an 83% increase in total income and revenues, driven by growing royalty and milestone receipts. This strong financial health is further bolstered by active business development, including the addition of 22 new assets and seven acquisitions, alongside a substantial $16 million share buyback program. While some pipeline updates are mixed, the overall financial results and strategic execution demonstrate robust growth and value creation, positioning the company for continued expansion in its royalty aggregation model.
At the time of this filing, XOMA was trading at $26.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $334.3M. The 52-week trading range was $18.35 to $39.92. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.